Introducing arginine residues into scFv in CAR-T cells shows promising antitumor effects. Maeta S, Fukunaga A, Egashira Y, Akahori Y, WANG L, Seo N, Atarashi Y, Ejima D, Fujiwara H, Shiku H. Molecular Therapy. 4;34(3):1421-1434. 2026
CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex. WANG L, Matsumoto M, Akahori Y, Seo N, Shirakura K, Kato T, Katsumoto Y, Miyahara Y, Shiku H. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex. Molecular Therapy. 170:116052. 2024
MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. Liu M, Akahori Y, Imai N, WANG L, Negishi K, Kato T, Fujiwara H, Miwa H, Shiku H, Miyahara Y. 32(3):734-748. 2024
